BSE: 524768 | NSE: | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Emmessar Biotech & Nutrition Ltd is a good quality company.
The key valuation ratios of Emmessar Biotech & Nutrition Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Emmessar Biotech & Nutrition Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -10.5% | -59.4% | 79.5% | 31.5% | 9% | 18.9% | 45.3% | 15.7% | 15% | 11.4% | - |
| Value Creation Index ⓘ | -1.8 | -5.2 | 4.7 | 1.3 | -0.4 | 0.4 | 2.2 | 0.1 | 0.1 | -0.2 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 2.2 | 2 | 2.6 | 1.3 | 0.6 | 3.4 | 7 | 0.4 | 1 | 0.6 | 1 |
| Sales YoY Gr. | - | -10.1% | 33.5% | -52.5% | -49.6% | 439.7% | 105.6% | -94.9% | 183.3% | -45.1% | - |
| Adj EPS ⓘ | -0.2 | 0.4 | 2.4 | 1.8 | 1.5 | 1.9 | 2.9 | 0.6 | 1 | 1.5 | 1.7 |
| YoY Gr. | - | NA | 555.6% | -22.5% | -19.7% | 27.9% | 54.3% | -79.7% | 69.5% | 50% | - |
| BVPS (₹) ⓘ | 2.8 | 1.8 | 4.2 | 6 | 7 | 8.5 | 11.4 | 12.4 | 13.3 | 14.8 | 15.6 |
| Adj Net Profit ⓘ | -0.1 | 0.2 | 1.2 | 0.9 | 0.7 | 0.9 | 1.5 | 0.3 | 0.5 | 0.8 | 1 |
| Cash Flow from Ops. ⓘ | 0 | 0.4 | 0.8 | 0.7 | 0.4 | 1 | 0.5 | 2.3 | 0.4 | 0.6 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 0 | 0.2 | 0 | 0 | 0 | 0.2 | 0.2 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -14.1% | -2.3% | -56.9% | -45.1% | ||||
| Adj EPS ⓘ | NA | 0.4% | -19.7% | 50% | ||||
| BVPSⓘ | 20.6% | 16.1% | 9.1% | 11.1% | ||||
| Share Price | 18.2% | 32.9% | 19.4% | 84.6% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -8.1 | 15.6 | 78.6 | 36 | 22.6 | 24.1 | 29.1 | 5 | 7.8 | 10.7 | 11.4 |
| Op. Profit Mgn % ⓘ | -6.5 | 0.6 | 8.6 | -33.3 | -101.6 | -11.9 | 12.1 | -242.5 | -67.1 | -194.3 | -118.5 |
| Net Profit Mgn % ⓘ | -5.5 | 9 | 44.8 | 72.9 | 116.5 | 27.6 | 20.7 | 80.9 | 49.2 | 135.3 | 105.5 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Working Cap Days ⓘ | 126 | 175 | 152 | 333 | 905 | 193 | 124 | 2,044 | 326 | 512 | 2,540 |
| Cash Conv. Cycle ⓘ | 63 | 64 | 40 | 39 | 187 | 47 | 57 | 1,347 | 38 | 84 | 2,355 |
Return on Equity has increased versus last 3 years average to 11.40%
Sales growth is good in last 4 quarters at 60.26%
Sales growth has been subdued in last 3 years -56.89%
Net Profit has been subdued in last 3 years -19.73%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 1.7 | - |
| TTM Sales (₹ Cr.) | 0.8 | - |
| BVPS (₹.) ⓘ | 15.6 | - |
| Reserves (₹ Cr.) ⓘ | 3 | - |
| P/BV ⓘ | 2.81 | - |
| PE ⓘ | 25.23 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 23.32 / 64.00 |
| All Time Low / High (₹) | 1.00 / 64.00 |
| Market Cap (₹ Cr.) | 21.9 |
| Equity (₹ Cr.) | 5 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 43 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.19 | 1.97 | 2.63 | 1.25 | 0.63 | 3.40 | 6.99 | 0.36 | 1.02 | 0.56 |
| Operating Expenses ⓘ | 2.33 | 1.96 | 2.41 | 1.67 | 1.27 | 3.80 | 6.14 | 1.26 | 1.71 | 1.64 |
| Manufacturing Costs | 0.93 | 0.41 | 0.73 | 0.39 | 0.25 | 1.37 | 1.63 | 0.04 | 0.05 | 0.05 |
| Material Costs | 0.80 | 1 | 0.98 | 0.63 | 0.12 | 1.54 | 3.53 | 0.13 | 0.40 | 0.20 |
| Employee Cost | 0.28 | 0.31 | 0.39 | 0.41 | 0.58 | 0.58 | 0.64 | 0.77 | 0.84 | 0.96 |
| Other Costs ⓘ | 0.32 | 0.24 | 0.31 | 0.24 | 0.32 | 0.31 | 0.34 | 0.32 | 0.42 | 0.43 |
| Operating Profit ⓘ | -0.14 | 0.01 | 0.23 | -0.42 | -0.64 | -0.40 | 0.85 | -0.89 | -0.69 | -1.08 |
| Operating Profit Margin (%) | -6.6% | 0.6% | 8.6% | -33.3% | -101.0% | -11.9% | 12.1% | -245.0% | -67.6% | -194.0% |
| Other Income ⓘ | 0.06 | 0.26 | 0.98 | 1.27 | 1.30 | 1.47 | 1.47 | 1.92 | 1.75 | 1.99 |
| Interest ⓘ | 0 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation ⓘ | 0.07 | 0.03 | 0.01 | 0.05 | 0.08 | 0.06 | 0.06 | 0.09 | 0.09 | 0.10 |
| Exceptional Items ⓘ | 0 | -0.92 | 0 | 0 | -0.29 | -0.26 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | -0.16 | -0.68 | 1.18 | 0.80 | 0.29 | 0.74 | 2.25 | 0.93 | 0.97 | 0.81 |
| Tax ⓘ | -0.04 | -0.21 | 0 | -0.12 | -0.24 | -0.02 | 0.80 | 0.46 | 0.46 | 0.06 |
| Profit After Tax | -0.12 | -0.47 | 1.18 | 0.91 | 0.53 | 0.75 | 1.45 | 0.48 | 0.50 | 0.75 |
| PAT Margin (%) | -5.4% | -23.6% | 44.8% | 72.9% | 84.7% | 22.2% | 20.7% | 130.3% | 49.4% | 135.0% |
| Adjusted EPS (₹) | -0.2 | -0.9 | 2.4 | 1.8 | 1.1 | 1.5 | 2.9 | 1.0 | 1.0 | 1.5 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 1.37 | 0.91 | 2.09 | 2.98 | 3.51 | 4.26 | 5.70 | 6.17 | 6.66 | 7.40 |
| Share Capital ⓘ | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves ⓘ | -3.62 | -4.09 | -2.91 | -2.01 | -1.49 | -0.73 | 0.70 | 1.17 | 1.67 | 2.41 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 0 | 0 | 0 | 0 | 0.07 | 0 | 0 | 0 | 0.08 | 0.11 |
| Long Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short Term Debt | 0 | 0 | 0 | 0 | 0.07 | 0 | 0 | 0 | 0.08 | 0.11 |
| Trade Payables | 0.31 | 0.20 | 0.20 | 0.01 | 0.58 | 0.80 | 0.50 | 0.02 | 0 | 0.01 |
| Others Liabilities ⓘ | 0.74 | 1.05 | 0.81 | 0.69 | 0.53 | 0.35 | 1.29 | 1.41 | 1.35 | 1.25 |
| Total Liabilities ⓘ | 2.42 | 2.16 | 3.11 | 3.68 | 4.68 | 5.41 | 7.49 | 7.60 | 8.09 | 8.77 |
Fixed Assets | ||||||||||
| Gross Block | 3.11 | 1.31 | 1.30 | 2.88 | 2.63 | 2.60 | 2.60 | 2.02 | 2.04 | 2.04 |
| Accumulated Depreciation | 1.68 | 0.58 | 0.58 | 0.63 | 0.64 | 0.68 | 0.74 | 0.56 | 0.65 | 0.74 |
| Net Fixed Assetsⓘ | 1.42 | 0.73 | 0.72 | 2.25 | 1.99 | 1.91 | 1.86 | 1.46 | 1.40 | 1.31 |
| CWIP ⓘ | 0 | 0 | 0.80 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investmentsⓘ | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Inventories | 0.69 | 0.36 | 0.32 | 0.09 | 0.73 | 1.15 | 0.07 | 0.07 | 0.14 | 0.09 |
| Trade Receivables | 0.04 | 0.36 | 0.04 | 0.03 | 0.04 | 0.03 | 2.71 | 0.01 | 0.01 | 0.02 |
Cash Equivalents  ⓘ
| 0.02 | 0.43 | 0.32 | 0.27 | 0.71 | 1.88 | 2.47 | 4.58 | 5.19 | 6.18 |
| Others Assetsⓘ | 0.24 | 0.27 | 0.89 | 1.03 | 1.21 | 0.44 | 0.38 | 1.47 | 1.35 | 1.16 |
| Total Assets ⓘ | 2.42 | 2.16 | 3.11 | 3.68 | 4.68 | 5.41 | 7.49 | 7.60 | 8.09 | 8.77 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -0.01 | 0.44 | 0.75 | 0.74 | 0.39 | 1.03 | 0.47 | 2.27 | 0.38 | 0.64 |
| PBT ⓘ | -0.16 | -0.68 | 1.18 | 0.80 | 0.58 | 1 | 2.25 | 0.93 | 0.97 | 0.81 |
| Adjustment ⓘ | 0.07 | 0.73 | 0.06 | 0.01 | -0.07 | -0.31 | -0.07 | -0.13 | -0.15 | -0.42 |
| Changes in Working Capital ⓘ | 0.08 | 0.39 | -0.45 | -0.02 | -0.12 | 0.34 | -1.61 | 1.76 | -0.5 | 0.24 |
| Tax Paid ⓘ | 0 | 0 | -0.04 | -0.05 | 0 | 0 | -0.10 | -0.29 | 0.06 | 0.02 |
| Cash Flow From Investing Activity ⓘ | 0 | -0.46 | -0.74 | -0.69 | -0.37 | -1.06 | 0.01 | -2.61 | -0.55 | -0.64 |
| Capex | 0 | -0.02 | -0.01 | -0.78 | 0 | 0 | 0 | -0.31 | -0.03 | 0 |
| Net Investments | 0 | 0 | 0 | 0.08 | -0.41 | -1.19 | -0.11 | -2.45 | -0.78 | -0.99 |
| Others ⓘ | 0 | -0.44 | -0.74 | 0.01 | 0.04 | 0.14 | 0.12 | 0.14 | 0.26 | 0.35 |
| Cash Flow From Financing Activityⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Cash Flow ⓘ | -0.01 | -0.02 | 0.01 | 0.05 | 0.01 | -0.03 | 0.48 | -0.34 | -0.17 | 0 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -7.98 | -40.75 | 78.73 | 36 | 16.42 | 19.4 | 29.1 | 8.01 | 7.85 | 10.66 |
| ROCE (%) | -10.49 | -59.37 | 79.46 | 31.46 | 9 | 18.87 | 45.29 | 15.71 | 14.99 | 11.42 |
| Asset Turnover Ratio | 0.98 | 0.89 | 1.03 | 0.39 | 0.15 | 0.67 | 1.08 | 0.05 | 0.13 | 0.07 |
| PAT to CFO Conversion(x) | N/A | N/A | 0.64 | 0.81 | 0.74 | 1.37 | 0.32 | 4.73 | 0.76 | 0.85 | Working Capital Days |
| Receivable Days | 17 | 36 | 27 | 10 | 21 | 3 | 71 | 1,362 | 4 | 11 |
| Inventory Days | 82 | 93 | 46 | 56 | 236 | 101 | 32 | 68 | 37 | 74 |
| Payable Days | 105 | 93 | 76 | 61 | 857 | 163 | 67 | 753 | 0 | 17 |
Emmessar Biotech & Nutrition Ltd., was originally started as Emmessar Chemical Industries Ltd on March 17,1992, for manufacturing Super Speciality Fine Chemicals. The Company succeeded in developing many Speciality Fine Chemicals in its own In-house R&D, which was recognised on January 15, 1996 by DSIR, Ministry of Science & Technology, Government of India, New Delhi .
When there was a realisation that some of the Speciality Chemicals developed in our R&D and exported to USA & Europe were being used in Healthcare formulations, the Company decided to re-orient itself and enter the Healthcare business, which is poised for phenomenal growth in the coming decades.
Concurrently the company also realised that some of the Speciality Chemicals are actually Vital Micro Nutrients, which are being used in the research worldwide as tools of Biotechnology, the Company took a conscious decision to enter the field of Biotechnology & Healthcare.
To ensure that the name is representative of its activity, the company's name was changed from Emmessar Chemical Industries Ltd., to Emmessar Biotech & Nutrition Ltd., on 7th April 2000.
In the process of pursuing its own R&D and exploring commercial market potentials for their products in the field of Healthcare, the company came across another reputed company in USA Vibrant Life in California.
Intense exchange of ideas & technical information between Emmessar Biotech & Nutrition Ltd., & Vibrant Life, resulted in development of several new concepts and new technologies - combining different schools of thought such as Nutraceuticals, Cosmeceuticals, Ayurveda & Biotechnology.
The company has developed many products covering different areas of healthcare that include obstinate Skin problems & debilitating chronic physical ailments.
Emmessar Biotech & Nutrition Ltd., is a Public Limited Company, with the Paid-up Share Capital of about Rs. 50.00 million (over $ 1.00 million). The Stocks of Emmessar Biotech & Nutrition Ltd., are traded in The Bombay Stock Exchange Ltd.
Product range of the company includes:
Present products
Products planned to be launched in future
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
